Cargando…

Adverse Drug Events Associated With Remdesivir in Real-World Hospitalized Patients With COVID-19, Including Vulnerable Populations: A Retrospective Multicenter Study

BACKGROUND: Remdesivir is a US Food and Drug Administration-approved drug for coronavirus disease 2019 (COVID-19). Clinical trials were conducted under strictly controlled situations for a selected population, and their reported adverse events may not fully represent conditions in real-world patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Hyein, Kang, Chang Kyung, Im, Jae Hyoung, Cho, Yoonsook, Kang, Dong Yoon, Lee, Ju-Yeun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643246/ https://www.ncbi.nlm.nih.gov/pubmed/37967875 http://dx.doi.org/10.3346/jkms.2023.38.e346

Ejemplares similares

Adverse drug events leading to emergency department visits: A multicenter observational study in Korea
por: Kang, Min-Gyu, et al.
Publicado: (2022)

Cardiac Adverse Events With Remdesivir in COVID-19 Infection
por: Gupta, Anupam K, et al.
Publicado: (2020)

Remdesivir vs tocilizumab in COVID-19: adverse event profiles
Publicado: (2021)

Remdesivir Use in the Real-World Setting: An Overview of Available Evidence
por: Akinosoglou, Karolina, et al.
Publicado: (2023)

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Potential Impact of the Involvement of Clinical Pharmacists in Antimicrobial Stewardship Programs on the Incidence of Antimicrobial-Related Adverse Events in Hospitalized Patients: A Multicenter Retrospective Study
por: Suh, Yewon, et al.
Publicado: (2021)

Remdesivir: Remedy the world is waiting for?
por: Suranagi, Umesh Devappa, et al.
Publicado: (2020)

Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Rafaniello, Concetta, et al.
Publicado: (2021)

Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea
por: Kang, Min-Gyu, et al.
Publicado: (2019)

Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2021)

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
por: Kim, Mijin, et al.
Publicado: (2020)

PIN82 Real-World Utilization of Remdesivir in 2020: A Retrospective Cohort Study
por: Mozaffari, E., et al.
Publicado: (2021)

Spontaneously Reported Hepatic Adverse Drug Events in Korea: Multicenter Study
por: Kwon, Hee, et al.
Publicado: (2012)

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
por: Oh, Shin Ju, et al.
Publicado: (2021)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
por: Lee, Chae Won, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Designing Adverse Event Forms for Real-World Reporting: Participatory Research in Uganda
por: Davies, Emma C., et al.
Publicado: (2012)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
por: Teimouri, Arezou, et al.
Publicado: (2022)

Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis
por: Gandham, Ravi, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
por: Ye, Byong Duk, et al.
Publicado: (2021)

Topiramate-related adverse events: Pattern and signals in the Korea Adverse Event Reporting System, 2010-2017
por: Choi, Junyeong, et al.
Publicado: (2020)

Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry
por: Ki, You-Jeong, et al.
Publicado: (2020)

Association between the Levofloxacin Plasma Concentration and Neurological Adverse Events in an Elderly Patient
por: Kang, Gaeun, et al.
Publicado: (2019)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
por: Cottini, Francesca, et al.
Publicado: (2021)

Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers
por: Lee, Dong Yeop, et al.
Publicado: (2023)

The Effectiveness of a Mobile Health Care App and Human Coaching Program in Primary Care Clinics: Pilot Multicenter Real-World Study
por: Ju, HyoRim, et al.
Publicado: (2022)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World Study
por: Kang, Danbee, et al.
Publicado: (2023)

USA stockpiling of remdesivir: How should the world respond?
por: Dawoud, Dalia, et al.
Publicado: (2020)

Real-World Estimates of Adrenal Insufficiency–Related Adverse Events in Children With Congenital Adrenal Hyperplasia
por: Ali, Salma R, et al.
Publicado: (2020)

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)

Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
por: Umetsu, Ryogo, et al.
Publicado: (2021)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis
por: Bang, Yeong Hak, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tjvp27kjb0nafiv00bo45rd9qt